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Our understanding of pancreatic ductal adenocarcinoma (PDAC) is shifting away from a
disease of malignant ductal cells-only, toward a complex system where tumor evolution is
a result of interaction of cancer cells with their microenvironment. This change has led to
intensification of research focusing on the fibrotic stroma of PDAC. Pancreatic stellate cells
(PSCs) are the main fibroblastic cells of the pancreas which are responsible for producing
the desmoplasia in chronic pancreatitis (CP) and PDAC. Clinically, the effect of desmoplasia
is two-sided; on the negative side it is a hurdle in the diagnosis of PDAC because the
fibrosis in cancer resembles that of CP. It is also believed that PSCs and pancreatic fibrosis
are partially responsible for the therapy resistance in pancreatic cancer. On the positive
side, a fibrotic pancreas is safer to operate on compared to a fatty and soft pancreas
which is prone for postoperative pancreatic fistula. In this review the impact of pancreatic
fibrosis on diagnosis of pancreatic cancer and surgical decisions are discussed from a
clinical point of view.
Keywords: microenvironment, stellate cells, angiogenesis, desmoplasia, periostin, cystic pancreatic tumors,
molecular diagnostics
INTRODUCTION
Pancreatic fibrosis (desmoplasia) is found both in chronic pan-
creatitis (CP) and pancreatic ductal adenocarcinoma (PDAC).
Pancreatic stellate cells (PSCs) are responsible for producing the
desmoplasia in both diseases. Pathophysiologically, desmoplastic
replacement of the normal parenchyma leads to the exocrine and
endocrine insufficiency of the pancreas. In pancreatic cancer, the
fibrotic stroma effect tumorigenesis, angiogenesis, therapy resis-
tance and possibly the metastatic spread of tumor cells (Bachem
et al., 2005; Vonlaufen et al., 2008b; Erkan et al., 2009; Xu et al.,
2010; Apte andWilson, 2012). Clinically, the effect of desmoplasia
is two-sided; on the negative side it is a hurdle in the diagno-
sis of PDAC because the fibrosis in cancer resembles that of CP.
This becomes even more important considering the fact that CP
is a risk factor for PDAC (Figures 1A,B). Here, fibrosis poses a
problem for the radiologists, surgeons, and pathologists. As it is
radiologically difficult to differentiate between tumor and desmo-
plasia, identification of tumor borders intraoperatively is also
difficult to define. This is getting to be a bigger problem as the
frequency of resections after neoadjuvant (radio-) chemotherapy
is increasing. In cases where there is a good response to the neoad-
juvant therapy, tumor tissue is replaced to a great extent with
fibrosis, creating a challenge for the pathologist during the frozen-
section analysis. On the positive side, after pancreatic resection, a
fibrotic pancreas is safer to anastomose (pancreatic head resec-
tion) or to oversew (the pancreatic stump after distal pancreate-
ctomy) compared to a fatty and soft pancreas. Here, pancreatic
fibrosis turns out to be an advantage during surgery as a soft pan-
creas might increase the postoperative fistula rate (Kurohi et al.,
2010; Lee et al., 2010). Various technical modifications have been
suggested to reduce the postoperative fistula rate in the case of a
soft pancreas. Therefore the consistency of the pancreas influences
intraoperative decision-making on how to perform the pancreatic
anastomosis. Although several aspects of PSC activity and ensuing
desmoplasia will be briefly described, this review focuses mainly
on PSCs and pancreatic stroma from a clinical point-of view.
PERIACINAR FIBROSIS AND CHRONIC PANCREATITIS LIKE
CHANGES AROUND THE TUMOR
Quiescent PSC belong to the stellate cell system consisting of
retinoid-storing cells in various organs (Erkan et al., 2012a).
In the pancreas, they are located in the periacinar spaces in
close proximity to the basal aspect of acinar cells, capillaries,
and terminal nerve fibers (Samkharadze et al., 2011; Apte and
Wilson, 2012). PSC extend their long cytoplasmic projections
along the base of adjacent acinar cells similar to that of pericytes
in the mammary gland. With their ability to secrete acetylcholine,
it is probable that one of their physiological functions in the
healthy pancreas is to form an electromechanical/humoral inter-
face between the nerve endings and the acini, thereby having
a role in the exocrine secretion of the pancreas (Phillips et al.,
2010). Judging by early activation markers like periostin, one
can observe in pancreatic diseases that the initial activation of
quiescent PSC and extracellular matrix (ECM) deposition takes
place in the periacinar spaces (Erkan et al., 2009, 2012c). This
type of CP-like changes surround the tumor like an umbra and
infiltrate the normal parenchyma (Figures 1C,D). It is likely that
deposition of ECM around the capillaries and nerve endings
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FIGURE 1 | Pancreatic cancer developing in the background of chronic
pancreatitis and immunohistochemistry of the activated stroma
between the cancer and the normal pancreas. (A) Computed
tomography of a chronic pancreatitis patient from 2009 showing pancreatic
calcifications. (B) Computed tomography of the same patients 3 years later
showing the increase of tissue around calcifications which is highly
suggestive of cancer development. (C) Notice the finger-like extension of
the activated stroma (marked by dotted lines) between the normal
pancreatic lobuli and the cancer. Periostin staining (brown) is made without
counterstaining. Original magnification 5x (D) strongest periostin
expression is found around degenerating acini/atypical flat lesions (black
arrows). Original magnification 50x.
interfere with the perfusion of the normal parenchyma and loss
of normal function (i.e., contraction of PSC and/or secretion of
ACh upon stimulation) of the quiescent PSC. Both in humans
and genetically engineered mouse models (GEMM), preneoplas-
tic lesions like pancreatic intraepithelial neoplasia (PanIN) and
atypical flat lesions are also commonly found in the activated
front of the stroma between the normal areas and the tumor
(Erkan et al., 2007a, 2012b,c). During chronic inflammation,
abundant presence of cytokines, ECM proteins and hypoxia may
all play a role in the initiation of carcinogenesis. For example in
GEMM, when pancreas specific activation of Kras was induced
in adult mice, it did not lead to carcinogenesis (Guerra et al.,
2007). However repetitive cerulein injections leading to pancre-
atitis induced metaplasia, dysplasia and eventually cancer in the
epithelial compartment in these adult mice (Guerra et al., 2007).
These changes were accompanied by the typical stromal reaction
observed in humans.
Similar to the situation in breast cancer, we have previously
argued that microenvironment may provide the “second hit” for
epithelial cells that possess tumorigenic potential (Sternlicht et al.,
1999; Barcellos-Hoff and Ravani, 2000; Radisky and Przybylo,
2008; Erkan et al., 2012c). Alternatively, the abnormal inter-
actions might lead to genomic instability within the epithelial
cells and the acquisition of tumorigenic potential (Barcellos-Hoff
and Ravani, 2000; Radisky and Przybylo, 2008; Guturu et al.,
2009; Masamune et al., 2009; Pandol et al., 2009; Radisky and
Radisky, 2010). The proliferating dysplastic and/or malignant
cells can then interact with their microenvironment and enhance
the abnormal interactions (Erkan et al., 2007a, 2009). The situ-
ation is similar in humans; patients with long-standing CP (e.g.,
hereditary CP) have an over 25-fold increased risk of develop-
ing pancreatic cancer compared with the normal population,
probably owing to long-standing inflammation (Lowenfels et al.,
1993).
WHAT IS THE REASON FOR PANCREATIC FIBROSIS IN
PANCREATIC DUCTAL ADENOCARCINOMA?
Histologically, periampullary tumors arise from four different cell
types. Compared to distal bile duct-, papillary-, and duodenal-
cancers, PDAC elicits a stronger pancreatic fibrosis. Although
painless jaundice is the most frequent symptom in all, due to
anatomic reasons, distal bile duct cancers for example obstruct
the bile duct before obstructing the pancreatic duct. As PDAC
originates from the pancreas, in some cases obstruction of
the pancreatic duct precedes biliary obstruction. Such patients
present sometimes with acute pancreatitis and pose a challenge
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to the clinician as it is very difficult to find the tumor in the
acutely inflamed pancreas (Figure 2A). Most of the pancreatic
head tumors (at the time of diagnosis) obstruct both ducts and
result in the typical double-duct-sign, that is a dilated bile duct
and a dilated pancreatic duct failing to merge due to the mass
effect of the tumor (Figures 2B,C). Although the prognosis of
PDAC is worst among the four, PDAC has in general the lowest
fistula rate after pancreatic head resection due to a simple dif-
ference (Bartoli et al., 1991). The pancreas is more fibrotic in
PDAC cases compared to the others. This observation is of course
unavoidably biased. A distal bile duct tumor (due to its localiza-
tion) becomes symptomatic (jaundice) in an earlier stage than a
PDAC that secondarily obstructs the bile duct. Hence the dura-
tion of the disease is different in the two scenarios. But why does
even a small PDAC elicit more fibrosis than a distal bile duct can-
cer does? And why does for example neuroendocrine cancers of
the pancreas elicit no fibrosis? (Figure 3A) The answer is two-
fold. Pancreatic cancer cells activate the PSC around them, and
this activation leads to the fibrosis of the tumor. There is plenty
of in vitro data supporting this observation. Alternatively, since
PDAC originates in the pancreatic ductal system, it obstructs the
smaller ductules or even the main pancreatic duct as an early
event. PSC distal to the lesion are activated as a consequence
of pancreatitis due to ductal obstruction and create pancreatic
fibrosis (Tanaka et al., 1988; Panozzo et al., 1995; Kloppel et al.,
2004; Erkan et al., 2007a, 2012b,a). The desmoplasia in PDAC is
a mixture of both mechanisms. Since most of the PDAC cases
are located in the pancreatic head (Figure 3B), the resected tis-
sue after a Whipple’s operation contains almost always the part of
the tumor-free pancreas distal to the tumor (with the exception
of tumors confined to the uncinate process). The pathological
analysis of the resection margin shows almost invariably CP like
changes. Due to the overlap of both mechanisms in pancreatic
head PDAC, it is not possible to dissect how much of the fibrosis
distal to the tumor is due to the activation of the PSC directly by
cancer cells and howmuch of it is secondary to ductal obstruction
and pancreatitis. To answer this question one should look at the
PDAC cases located in the body of the pancreas. In such cases, the
proximal part of the tumor-free pancreas is not as fibrotic as the
distal part. Proximally, in many cases, one can see a sharp mar-
gin between the normal parenchyma and the fibrotic tumor. This
margin is more difficult to see distally (Figure 3C). This differ-
ence is due to the absence of ductal obstruction and pancreatitis
proximal to the tumor and shows the real extent of cancer spe-
cific fibrosis. Therefore, distal bile duct tumors which become
symptomatic due to jaundice create almost no fibrosis in the nor-
mal pancreas increasing the fistula rate after a pancreatic head
resection (Figure 3D).
HOW DOES PANCREATIC FIBROSIS INFLUENCE
INTRAOPERATIVE DECISION-MAKING?
Perhaps the most serious complication after pancreatic resections
is the pancreatic fistula. It is a major source of postoperative
morbidity and is associated with several further complications,
such as intra-abdominal abscess, wound infection, sepsis, mal-
absorption, and haemorrhage (Knaebel et al., 2005). Sepsis and
hemorrhage after pancreaticoduodenectomy are associated with
a mortality rate of 20–40% (Shrikhande et al., 2005). Pancreatic
fistula and its consequences lead to decreased quality of life, loss
of work power, development of resistant bacteria, and a finan-
cial burden for the health system (Diener et al., 2011). Soft
and friable pancreatic parenchyma, makes the anastomosis dif-
ficult to perform. A review of 2644 patients in 1991 reported
a fistula rate of 5% in CP, 12% in pancreatic cancer, 15% in
ampullary cancer, and 33% in bile duct cancer (Bartoli et al.,
1991). Other studies have supported the association of soft pan-
creas with higher leak rates (Sato et al., 1998). As of today there
are various attempts to reduce the postoperative pancreatic fis-
tula rate. Such attempts range from the perioperative usage of
Octreotide© (somatostatin analog) to modifications of the surgi-
cal technique (see below). Regarding the inhibition of pancreatic
secretion to reduce pancreatic fistula rate; a recent systematic
review and meta-analysis concluded that there is no solid evi-
dence that somatostatin analogs result in a higher closure rate of
pancreatic fistula compared with other treatments (Gans et al.,
2012).
FIGURE 2 | Cross sectional imaging showing secondary changes due
to pancreatic cancer. (A) Computed tomography of a pancreatic head
adenocarcinoma (histologically confirmed after resection) obstructing the
pancreatic duct and creating pancreatitis which makes the tumor very
difficult to detect. The typical double duct sign created by pancreatic head
tumor detected by computed tomography (B). Notice the dilated bile-and
pancreatic-ducts failing to merge. The locally advanced tumor is not
directly visible in the background of pancreatitis (calcifications appear as
white spots in the pancreatic head). (C) Reconstruction of T2-weighted
imaging (magnetic resonance cholangio-pancreatography) showing the
same phenomenon in another patient (fluids appear white in T2-weighted
sequences).
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FIGURE 3 | Panreatic fibrosis is influenced by the localization and the type
of the tumor. (A) The resected pancreatic body is cut open along the white
double headed arrow. Notice the lack of fibrosis around the neuroendocrine
tumors. (B) The resected pancreatic head is cut open along the white double
headed arrow. Red dotted line marks the desmoplastic pancreatic head tumor,
where it ismacroscopically not possible to differentiate between the tumor and
the pancreatic fibrosis. Blue dotted line marks the preserved normal uncinate
process. Green line marks the touché marked retroperitoneal margin for the
microscopic assessment of the R-Status of the resection. (C) The resected
pancreatic body is cut open longitudinally in the middle. Notice the proximal
demarcation of the desmoplastic tumor from the normal lobular pancreas.
Distally however, due to the ductal obstruction and repetitive pancreatitis
bouts, pancreas is atrophic and fibrotic. (D) The resected pancreatic head is cut
open along the white double headed arrow. White dotted line marks the small
distal bile duct tumor. Notice the lack of fibrosis and dilatation of the pancreatic
duct despite massive dilatation of the bile duct.
TECHNICAL MODIFICATIONS TO REDUCE PANCREATIC
FISTULA RATE AFTER PANCREATIC HEAD RESECTIONS
Pancreatic head resections are mostly performed due to cancer,
followed by CP, cysts, trauma, or infiltration of duodenum by
other cancers (Lillemoe et al., 1999; Kleeff et al., 2007). After a
pancreatic head resection the distal pancreas has to be connected
with the alimentary tract. This step is the most critical part of
the Whipple’s operation. The most commonly performed type of
anastomosis ismadewith a jejunal loop (Figure 4A). Alternatively
the posterior wall of the stomach is used to implant/anastomose
the distal pancreas (Figure 4B). Although many non-randomized
observational clinical studies show the superiority of pancreatico-
gastrostomy over pancreaticjejunostomy, randomized-controlled
trials failed so far to show the superiority of either technique (Yeo
etal., 1995b;Bassi etal., 2005b;Duffasetal., 2005;Wenteetal., 2007;
Fernandez-Cruz et al., 2008). Clinically relevant pancreatic fistula
rate (grade B or C in International Study Group on Pancreatic
Fistula classification), (Bassi et al., 2005a) after pancreatic head
resections is generally less than 15% in reference centers (Yeo et al.,
1995a; Bassi et al., 2005b; Winter et al., 2006; Fernandez-Cruz
et al., 2008).
There are a number of detailed reviews on the various
techniques on how to reduce pancreatic leak rate after pancre-
atic resections (Shrikhande et al., 2005; Poon and Fan, 2008).
Therefore, we will briefly mention some techniques that have
failed to decrease the leak rate and focus on three randomized
controlled trials (two on pancreatic head resections and one on
distal pancreatectomy) where a significant reduction was achieved
due to technical modifications. Pancreatic duct occlusion has
been abandoned due to high rate of complications (exocrine
and endocrine pancreatic insufficiency) and low rate of success
(Goldsmith et al., 1971; Di Carlo et al., 1989; Tran et al., 2002).
In order to buttress the anastomosis, well-vascularized struc-
tures have been wrapped around the anastomosis. The most
commonly used tissues are the omentum and the falciform liga-
ment. Recently, the Japanese Society of Pancreatic Surgery (JSPS)
performed a nationwide survey to evaluate whether wrapping
using the omentum/falciform ligament can help to prevent post-
operative complications after pancreatic head resections (Tani
et al., 2012). Analysis of the data from 2597 cases did not show
any reduction of fistula by wrapping. In fact, a pancreatic fistula
occurred in 623 patients (37.3%) in the non-wrapping group,
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FIGURE 4 | Intraoperative pictures of various pancreatic anastomosis. (A) Pancreas is anastomosed to a diverted jejunal loop. (B) Pancreas is inserted in
the posterior wall of the stomach. The anastomosis is made through a separate incision made on the anterior wall of the stomach.
whereas 393 patients (42.8%) developed fistula in the wrapping
group (P = 0.006). The incidence of a grade B or C pancreatic
fistula was also lower in the non-wrapping group than the wrap-
ping group (16.7% vs. 21.5%; P = 0.002). However due to the
retrospective and non-randomized structure of this study, it is
not possible to conclude that wrapping itself is a risk factor. It is
likely that the surgeons anticipating complications due to a risky
pancreas took this additional measure (Tani et al., 2012).
Internal duct stenting may help to divert pancreatic secre-
tions from the anastomosis and allow more precise placement of
sutures, thus protecting the pancreatic duct from suture injury
and reducing the chances of inadvertent pancreatic duct occlusion
(Shrikhande et al., 2005). Roder et al. has shown in a prospective
but non-randomized study in 85 patients where a stented pancre-
atic duct decreased the pancreatic leakage rate to 29.3% from 68%
and reduced the median hospital stay from 29 to 13 days (Roder
et al., 1999). However these results have not been confirmed by
randomized studies (Winter et al., 2006).
On the other hand, two randomized controlled prospective
clinical trials showed significant reduction of pancreatic leakage
rate using an external diverting stent after PJ anastomosis (Poon
et al., 2007; Pessaux et al., 2011). In the first study by Poon
et al. 120 patients undergoing pancreaticoduodenectomy with
end-to-side pancreaticojejunal anastomosis were randomized to
have either an external stent inserted across the anastomosis to
drain the pancreatic duct (n = 60) or no stent (n = 60). Duct-to-
mucosa anastomosis was performed in all cases. Both groups were
comparable in demographic data, underlying pathologies, pan-
creatic consistency, and duct diameter. In this study stented group
had a significantly lower pancreatic fistula rate compared with
non-stented group (6.7% vs. 20%, P = 0.032). On multivariate
analysis, no stenting and pancreatic duct diameter <3mm were
significant risk factors of pancreatic fistula (Poon et al., 2007).
More recently, Pessaux et al. showed similar results on
158 patients in a randomized prospective controlled trial with
soft pancreas and a diameter of wirsung <3mm. (Pessaux
et al., 2011). Again, both groups were comparable in terms of
demographic data, underlying pathologies, presenting symptoms,
presence of comorbid illness, and proportion of patients with
preoperative biliary drainage. Also in this study, stented group
had a significantly lower overall pancreatic fistula (26% vs. 42%;
P = 0.034).
In our opinion pancreatic surgeons must have more than one
technique for managing the pancreatic stump in their armamen-
tarium. It is nevertheless not possible to eliminate pancreatic
fistula completely. Due to the anatomic proximity to major ves-
sels, once they occur, pancreatic fistulas should be controlled as
fast as possible to prevent bleeding due to erosion of vessels (i.e.,
the stump of gastroduodenal artery or portal vein anastomosis
after an extensive tumor resection involving the portal vein). As
of today, most of the pancreatic fistulas can be managed conser-
vatively or with the help of interventional radiology. However, if
a postoperative pancreatic fistula cannot be managed by mini-
mal invasive techniques (i.e., percutaneous drainage), completion
pancreatectomy is performed as a salvage operation.
TECHNICAL MODIFICATIONS TO REDUCE PANCREATIC
FISTULA RATE AFTER DISTAL PANCREATECTOMY
Resections of the pancreas reaching to the left of the superior
mesenteric vein are defined as distal pancreatectomies. In the
1980 s and 1990 s most distal pancreatectomies were done elec-
tively as a result of pancreatitis, other benign diseases, ductal
adenocarcinoma, neuroendocrine tumors, and pancreatic pseu-
docysts. Some remaining small percent were emergency cases
after abdominal trauma or miscellaneous pathological diagnoses
(Lillemoe et al., 1999). In the last two decades, there is a dra-
matic surge in performing distal pancreatectomies due to cystic
tumors of the pancreas (Kleeff et al., 2007; Beane et al., 2011;
Diener et al., 2011; Ferrone et al., 2011). Recently the DISPACT
trial was designed to assess the effect of stapler versus hand-
sewn closure on formation of postoperative pancreatic fistula
after distal pancreatectomy (Diener et al., 2011). This multicen-
ter, randomized, controlled trial done in 21 European hospitals
recruited 450 patients, of whom 352 patients (177 stapler, 175
hand-sewn closure) were analyzed. Pancreatic fistula rate did not
significantly differ between stapler (32%) and hand-sewn closure
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(49%) (Diener et al., 2011). This study showed however the high
fistula rate (grade A–C fistula) of approximately 40% after distal
pancreatectomy.
Various attempts have been made to reduce the pancreatic
fistula rate after distal pancreatectomy as well. Except of one
recent study, none of the randomized controlled trials showed a
reduction in pancreatic fistula rate. For example, Frozanpor et al.
showed that prophylactic transpapillary pancreatic stent insertion
didn’t have any effect on clinically significant leak rate following
distal pancreatectomy (Frozanpor et al., 2012). Clinically sig-
nificant pancreatic fistula (Grade B or C) occurred in (22.2%,
without stent) and (42.3% with stent P = 0.122). In another
attempt, two different studies couldn’t show any benefit from
temporary occlusion of the main pancreatic duct with fibrin glue
(Suzuki et al., 1995; Suc et al., 2003).
Recently however, in a single-blinded, parallel-group, random-
ized controlled trial comparing stapled left pancreatectomy with
stapled left pancreatectomy using mesh reinforcement of the sta-
ple line with either Seamguard© or Peristrips Dry©, Hamilton
et al. could show a significant reduction of ISGPF grade B or C
fistula (Hamilton et al., 2012). In this study, clinically significant
fistulas were seen in 1.9% of patients undergoing resection with
mesh reinforcement and 20% of patients without mesh reinforce-
ment (P = 0.0007). According to this study, reinforcing the staple
line with some form of mesh buttress material appears to lessen
the risk of clinically significant fistula (Hamilton et al., 2012). It
is likely that a mesh buttress allows compression and stapling of
even a friable pancreas with more safety.
Although an anastomosis between the jejunal loop and the
pancreas is a more complex surgical procedure than simple clo-
sure of the pancreatic remnant, the fistula rate is significantly
higher after distal pancreatectomies compared to pancreatic head
resections. The most important factor related to pancreatic fistula
is the consistency of the pancreas. As mentioned above, after a
pancreatic head resection, the pancreas to be anastomosed is dis-
tal to the tumor, hence fibrotic. On the other hand, after a distal
pancreatectomy, the pancreas stump to be oversewn is proximal
to the tumor hence not fibrotic in most cases.
Due to the low success rate of non-surgical therapies in PDAC,
aggressive surgical approaches in reference centers are justified,
since resection provides the only chance of cure for some, and the
best palliation for most of the patients (Michalski et al., 2008a,b;
Kato et al., 2012; Strobel et al., 2012; Winter et al., 2012). Many
cases which were not candidates for surgical resection previously
are now offered surgical resection within the framework of stud-
ies analyzing the effect of neoadjuvant therapy in PDAC. Such
cases are especially prone to postoperative complications due to
extensive surgery, frequent vascular resections, and due to the
negative impact of preoperative radio/chemotherapy on healing,
which has already been shown in other tumors (Allendorf et al.,
2008; Stumpf et al., 2009; Strobel et al., 2012; Vande Walle et al.,
2012). The information on pancreatic stroma after radiotherapy
is very limited. Ishikawa et al. were the first ones to show that the
risk of pancreatic fistula decreased with preoperative radiotherapy
as it decreased the pancreatic secretion (Ishikawa et al., 1991). We
have previously shown that PSC are activated in vitro after radio-
therapy and resected tissues of patients after radiotherapy contain
acellular areas of fibrosis (Erkan et al., 2007a). However the detri-
mental effect of radiotherapy on the healing is mostly due to the
thrombosis of the vessels in the target field masking the influence
of tissue fibrosis enabling a safer anastomosis. Although rarely
performed, patients undergoing extensive surgery are always pre-
operatively informed about the possibility of performing a total
pancreatectomy to prevent a risky anastomosis where vascular
resections are concomitantly performed. During the operation,
one of the most important factors that the surgeon takes into con-
sideration while performing pancreatic surgery is the consistency
of the pancreas. In our and others’ experience, a high fat content
and a fragile pancreas are more risky to operate than a fibrotic
pancreas. In line with this observation Lee et al. have quanti-
tatively analyzed the degrees of pancreatic fatty infiltration and
fibrosis preoperatively using magnetic resonance imaging (MRI)
(Lee et al., 2010). They detected that patients with a fatty pancreas
developed more often postoperative pancreatic fistula. Recently,
in a single-center prospective observational study, Ansorge et al.
have stratified the pancreas consistency and pancreatic duct diam-
eter in patients undergoing a pancreaticojejunostomy during
pancreatic head resection (Ansorge et al., 2012). The morbidity
rate attributable to pancreaticojejunostomy was 22% and the clin-
ically relevant fistula rate (grade B or C) was 16%. They could
show that both soft pancreas and small pancreatic duct size were
risk factors for pancreatic fistula (Ansorge et al., 2012). They con-
cluded that a high risk pancreas (soft and small caliber duct)
had a 25-fold increased risk for postoperative fistula compared to
low risk pancreas (hard, big caliber duct) (Ansorge et al., 2012).
In a former study, Gaujoux et al. have shown that BMI > 25,
fatty pancreas and absence of fibrosis in the pancreatic remnant
were significant risk factors for pancreatic fistula (Gaujoux et al.,
2010). Taken together these data suggest that preoperative radi-
ological or intraoperative clinical evaluation by an experienced
surgeon showing lack of fibrosis and fatty pancreas may influence
the surgical decision-making such as anastomosis type, perform-
ing a total pancreatectomy, stenting the pancreatic duct, or usage
of Octreotide© postoperatively to reduce/prevent the pancreatic
fistula rate. Whether these measures influence the outcome is a
matter of ongoing debate.
According to Okabayashi et al., other factors may influence
the rate of fistula after pancreatic head resections. In a retro-
spective analysis of 50 cases undergoing pancreatoduodenectomy,
multivariable analysis identified (in addition to the absence of
fibrotic texture of the pancreas), elevated serum amylase levels
(more than 1.7-fold of the normal value) on the first postoper-
ative day, and not having early postoperative enteral nutrition as
risk factors for developing pancreatic fistula (Okabayashi et al.,
2007). It is known that ongoing pancreatitis is a risk factor for
healing after pancreatic resection (Erkan et al., 2007b). Therefore,
it is likely that elevated serum amylase levels on the first post-
operative day are due to some sort of pancreatic inflammation
endangering the anastomotic integrity. The authors conclude that
early enteral feeding may reduce the rate of pancreatic fistula
(Okabayashi et al., 2007). However, failing to initiate enteral
nutrition timely may hint (as a surrogate marker) a complicated
postoperative phase and not be per se a positive factor impact-
ing on the healing of the anastomosis. Due to the low number of
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cases, retrospective type of analysis, the results of this study needs
further validation.
ANTIFIBROTIC THERAPY IN PANCREATIC CANCER:
THEORETIC BENEFIT AND RISKS
Most of the research on PSC has focused on their roles in the
diseased pancreas. The amount of information on the role of qui-
escent PSC in the normal pancreatic physiology is scarce. This
is mainly due to spontaneous activation of PSC on plastic dur-
ing cultivation. Once the PSC are activated it is not easy to
revert this myofibroblast-like phenotype into quiescence again.
It is unknown how much resemblance exists between the acti-
vated PSC in vitro to that of physiologic activation in vivo. In
experimental models, there is a symbiotic relationship between
pancreatic cancer cells and PSC (that are already activated on
plastic) that results in an overall increase in the growth rate and
therapy resistance of the tumor (Erkan et al., 2010). For example,
orthotopic cancers induced in nude mice grow faster and have
an increased number of regional and distant metastases when
pancreatic cancer and stellate cells are injected together (Bachem
et al., 2005; Hwang et al., 2008; Vonlaufen et al., 2008a,b; Xu
et al., 2010). There is a general belief that PSC are coopted by
cancer cells to foster malignancy, thus antifibrotic therapies are
suggested to improve the response rate of PDAC (Erkan et al.,
2007a; Vonlaufen et al., 2008b; Diop-Frimpong et al., 2011; Apte
and Wilson, 2012). One can find dramatic titles in the litera-
ture like “Dangerous liaisons: PSCs and pancreatic cancer cells,”
“ PSCs and pancreatic cancer cells: an unholy alliance,” “PSCs:
partners in crime with pancreatic cancer cells” supporting the
premalignant role of PSC (Vonlaufen et al., 2008a,b; Apte and
Wilson, 2012).
It is a reality that conventional and targeted therapies which
work wonderfully in vitro or in animal experiments, fail to
show a similar effect in clinical trials (Kessenbrock et al., 2010;
Kindler et al., 2010; Conroy et al., 2011). This observation can
be explained by various differences between human and mouse
pancreatic tumors. For example the pattern of onset of cancer is
completely different in GEMM than in humans (focal in humans,
global and synchronized in mouse models). We have previously
argued that the discrepancy between experimental results and
the clinical reality might in part result from the inefficiency of
our current experimental setups and animal models in recreating
the tumor microenvironment and the fibrotic stroma of PDAC.
There is a new trend toward antifibrotic therapies combined with
chemotherapy (Erkan et al., 2012b,c). The preliminary encour-
aging results of such therapies are coming from genetic mouse
models for PDAC. In GEMM, antifibrotic therapies (i.e., inhibi-
tion of hedgehog signaling or enzymatic digestion of ECM com-
ponents) applied concomitantly with chemotherapy lead to an
increase in the drug penetrance to the tumor and longer survival
of the tumor bearing animals (Olive et al., 2009; Jacobetz et al.,
2012). The main rationale behind addition of antifibrotic ther-
apy to chemotherapy in PDAC is to make cancer cells which are
scattered in a safe haven of fibrosis more accessible for chemother-
apeutic agents. As of today data from clinical studies are largely
missing. However, as a proof of principle, Von Hoff et al. used
in a Phase I/II trial nanoparticle albumin-bound (nab) paclitaxel
(to deplete the stoma in PDAC) alone and in combination with
gemcitabine and showed that through depletion of stroma, higher
concentrations of gemcitabine can be delivered in the tumor (Von
Hoff et al., 2011).
Although these arguments are valid, the most important prob-
lem in PDAC is late diagnosis. It remains unknown if such
antifibrotic therapies combined with chemotherapy could con-
vert locally irresectable tumors to resectable ones. Unfortunately,
most of the patients have already distant metastasis at the time of
diagnosis and even many of the resectable ones have subclinical
metastatic disease. Considering this late time of diagnosis, antifi-
brotic therapies at this stage could be a double-edged sword. It
is not known for sure whether fibrosis acts only as a barrier for
chemotherapy or also as a defense against tumor spread. Why
should a normal cell support carcinogenesis? As of today, there is
no data showing any mutations in PSC originating from PDAC.
The innate reaction to form fibrosis is to build a barrier between
any noxious stimuli and the body. Fibrosis happens in the form of
callosity if one wears a shoe that does not properly fit. It is com-
monly observed from the feet of the ballerina to the hands of the
workers. Fibrotic capsule is found around parasitic cysts (Filippou
et al., 2004). In tumor biology, fibrotic capsule formation is a
defensive reaction coming from the stroma around the tumor,
and tumors with a capsule have better prognosis than infiltrative
tumors without a capsule (Lunevicius et al., 2001). In PDAC, col-
lagen deposition has a favorable impact on patient survival (Erkan
et al., 2008). At the first glance these arguments may seem to con-
tradict in vitro and other experimental (animal) data showing the
cooption of PSC to support tumor growth. In fact they do not.
According to the prevailing model of tumor progression,
human tumors develop through a succession of genetic and epi-
genetic changes that confer increasingly malignant characteristics
on cells. In 2000, Hanahan and Weinberg distilled properties of
cancers into six essential alterations in cell physiology that collec-
tively dictate malignant growth: self-sufficiency in growth signals,
insensitivity to growth-inhibitory (antigrowth) signals, evasion of
programmed cell death (apoptosis), limitless replicative poten-
tial, sustained angiogenesis, and tissue invasion and metastasis
(Hanahan and Weinberg, 2000). This review was updated in
2011 and a significantly greater focus on the importance of the
tumor microenvironment was added (Hanahan and Weinberg,
2011). Gatenby and Gillies argue that these steps are necessary
but not sufficient to produce invasive cancer. In their opinion car-
cinogenesis requires tumor populations to surmount six distinct
microenvironmental proliferation barriers that arise in the adap-
tive landscapes of normal and premalignant populations growing
from epithelial surfaces (Gatenby and Gillies, 2008). These bar-
riers are: apoptosis with loss of basement membrane contact,
inadequate growth promotion, senescence, hypoxia, acidosis, and
ischemia (Gatenby and Gillies, 2008). Somatic evolution of inva-
sive cancer can then be viewed as a sequence of phenotypical
adaptations to these barriers. For example, in PDAC, negative
selection of hypoxia resistant clones that down-regulate Bnip3
(a hypoxia inducible pro-apoptotic member of the Bcl-2 fam-
ily), gain cross-resistance against gemcitabine, and 5-FU (Erkan
et al., 2005). Importantly this selection occurs gradually onward
from PanIN II, through PanIN III into PDAC (Erkan et al.,
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2005). In human tissues and GEMM in which PanIN lesions are
detectable, a gradual increase in stromal activity and ECM depo-
sition is observed along with progress of the lesion where various
genetic mutations accumulate (Erkan et al., 2012b). The fibro-
sis and hypovascularity are believed to create hypoxia in PDAC
(Koong et al., 2000a,b; Erkan et al., 2009). Since the activation
of stroma/PSC occurs mostly around preneoplastic lesions like
PanIN- or atypical flat-lesions, ideally, the timing of interfering
with cancer–stromal interactions and/or elimination of the ECM
should not be at the invasive stage, but in earlier stages of carcino-
genesis before the adaptation and selection of aggressive clones
that can survive in the barrenmicroenvironment of PDAC (Erkan
et al., 2012b). As of today the only type of premalignant lesion that
can be detected by conventional radiology are the cystic tumors.
LATE DIAGNOSIS: THE MAIN THERAPEUTIC HURDLE
IN THE TREATMENT OF PDAC
Due to the insidious course of the disease, retroperitoneal local-
ization of the pancreas (disabling easy access), and lack of specific
symptoms and tumor markers suitable for screening (such as
PSA in prostate cancer), most pancreatic cancer patients are diag-
nosed at an advanced stage. Therapeutic time window for a tumor
can be described as the period of time from the diagnosis of the
earliest removable preneoplastic lesion to the locally advanced-
or metastatic-stage of a cancer where cure is no longer possi-
ble. For example, with the advent of endoscopic screening, for
most of the colorectal cancer cases, the therapeutic time window
from the appearance of a removable benign polyp to the develop-
ment of invasive cancer is on average more than a decade (Fearon
and Vogelstein, 1990; Kinzler and Vogelstein, 1996). In contrast,
almost all cases of PDAC patients are practically diagnosed at an
incurable stage, thereby with a closed therapeutic time window.
However in cystic pancreatic tumors, surgery performed at a pre-
invasive stage is curative as much as the preventive removal of a
premalignant colorectal polyp. Although there are several inher-
ent biological differences between PDAC and cystic malignant
pancreatic tumors, once the invasive stage has been reached, the
prognosis of intraductal papillary mucinous cancer can be as bad
as that of PDAC (Maire et al., 2002; Wada et al., 2005). Therefore,
the most important factor impacting on patient survival is the
early detection of the lesion at a preinvasive stage. The advan-
tage in the diagnosis of cystic tumors is that they are detectable in
a preinvasive stage with conventional radiological methods due
to their bigger size (in comparison with PanIN lesions) and the
high contrast between the cystic tumor and the normal pancreas
(Figure 5). The closed and open therapeutic time windows for
cystic pancreatic tumors versus PDAC, respectively is depicted in
Figure 6.
THE ONLY CONVENTIONALLY DETECTABLE PRECANCEROUS
LESIONS OF THE PANCREAS: CYSTIC TUMORS
Cystic tumors of the pancreas are being diagnosed with an
increasing frequency. It is still unclear if this is due to an increase
in the incidence of cystic tumors, or due to an increase in the
sensitivity of the diagnostic methods. Laffan et al. reported a
frequency 2.6% for unexpected cystic lesions detected in the
pancreas during an abdominal tomography performed in a
population of adult outpatients imaged for disease unrelated to
the pancreas (Laffan et al., 2008). Although there are more than
20 different cystic pancreatic tumor entities, approximately 90%
of the lesions are intraductal papillary cystic neoplasms (IPMN),
mucinous cystic neoplasms (MCN), solid-pseuodpapillary neo-
plasms (SPN) or serous cystic neoplasms (SCN) (Fernandez-del
Castillo and Warshaw, 2001). SCN have almost invariably a
benign course and rarely need surgical therapy (Kosmahl et al.,
2004; Matsumoto et al., 2005). On the other hand IPMN, MCN,
and SPN have a significant risk or malignant transformation, and
surgery is indicated in cases where other criteria are also sug-
gesting malignancy (Kosmahl et al., 2004; Reddy et al., 2004;
Salvia et al., 2004; Sohn et al., 2004; Matsumoto et al., 2005;
Tang et al., 2005; Tanaka et al., 2006). These cystic tumors of
the pancreas are in fact premalignant lesions which are curable
if resected in the preinvasive phase. However due to the com-
plexity of pancreatic surgery with a considerable morbidity and
mortality, reliable criteria for malignant transformation should
be defined. In 2006 Tanaka summarized the consensus guide-
lines (Sendai criteria) for the management of IPMN and MCN
(Tanaka et al., 2006). Depending on the cellular type; IPMN can
be gastric type (best survival), oncocytic type, intestinal type, or
pancreatobiliary type (worst survival) (Furukawa et al., 2011).
Depending on their localization they can be main duct type,
branch duct type, or mixed type (Tanaka et al., 2006). Six years
later, these criteria have been revised in the light of accumulating
data (Tanaka et al., 2012). In this revision, the criteion for char-
acterizing main duct-IPMN has been lowered to main pancreatic
duct dilation of >5mm. “High-risk stigmata” and “worrisome
features” have been defined to stratify the risk of malignancy
in branch duct-IPMN and consider resection or increased fre-
quency of surveillance. Resection is still recommended in all
surgically fit patients with main duct-IPMNorMCN. The indica-
tions for resection of branch duct-IPMN became more conserva-
tive. Branch duct-IPMNs of >3 cm without “high-risk stigmata”
can be observed without immediate resection (Tanaka et al.,
2012).
The situation for PDAC in comparison is much worse. As of
today perhaps the only lesion that can be described as in situ
PDAC is PanIN III. However it is almost impossible (excluding
some very rare cases of familial PDAC operated on prophylacti-
cally) to find PanIN III without PDAC, making the progress from
premalignant lesions to overt cancer very difficult to follow. The
major problems in detecting early lesions in PDAC are; the small
size of the premalignant lesions (micrometer to millimeter) and
the similarity of the fibrotic stroma seen both in CP and PDAC
masking the tumor in the fibrotic stroma.
THE LIMITS OF CONVENTIONAL RADIOLOGY IN DETECTING
CYSTIC AND SOLID TUMORS OF THE PANCREAS
As of today, the diagnosis and staging of PDAC is mostly done
using computed tomography (CT) orMRI. Although endosonog-
raphy is a valuable tool in experienced hands, it is also very
much user-dependent (Shankar and Russell, 2001; Canto, 2007;
Rozen et al., 2009; Canto et al., 2012). Radiologic detection of
a tumor is easy when the tumor looks different than the rest
of the organ it originates from. The exact principles of how CT
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FIGURE 5 | A case of main duct intraductal papillary mucinous cancer
necessitating total pancreatectomy: Fluids appear white in T2-weighted
images. Notice the several cystic lesions in the pancreatic head (white
circle, A) and the body/tail (white ellipse, B). (C) The resected pancreatic
head is cut open along the black double headed arrow showing the cystic
deformities and fibrotic stroma of the invasive cancer. The Hematoxlin and
Eosin staining of an area showing invasive cancer with abundant stroma is
shown as inset. The circles mark the desmoplastic pancreatic head tumor.
(D) The resected pancreatic body/tail is cut open longitudinally in the middle.
Notice the cystic dilatation of the pancreatic duct and the atrophic and fatty
pancreas. Hematoxylin and Eosin staining of a region with high grade
intraepithelial neoplasia is shown as inset, original magnification 50x.
and MRI work are beyond the scope of this article. Nevertheless
contrast enhancement of the tissues to make tumor and non-
tumor appear different is a basic concept for both. Contrast agents
are given intravenously and orally to make the vessels and the
luminal parts of the gastrointestinal system visible, respectively.
In fact, contrast uptake of a tumor is a function of its vas-
cularity, perfusion, and the consistency of its tissue (i.e., fatty,
fibrotic). PDAC is a hypovascular tumor and the interactions
of PSC and pancreatic cancer cells are believed to be one of
the reasons of this hypovascularity in vivo (Erkan et al., 2009).
Moreover due to increased interstitial pressure within a stiff
stroma and frequently encountered pathological vessels, the per-
fusion of the tumor is further hindered (Perez-Mancera et al.,
2012). This hypoperfusion is seen radiologically as delayed con-
trast uptake in comparison to normal pancreas (Erkan et al.,
2012b) (Figures 7A,B). However this hypovascularity is always a
relative phenomenon since the amount of fat and fibrosis in the
non-tumorous pancreas varies between the patients increasing
or decreasing the contrast between the tumor and the “nor-
mal” pancreas. In some cases there is no difference between the
tumor and the rest of the pancreas despite high suspicion of a
tumor (i.e., due to abrupt obstruction of the biliary/pancreatic
ductal system). When compared with a good quality contrast
enhanced CT, the additional information acquired by MRI is
higher in cystic tumors than in PDAC (Figures 5A,B, 7C). As
of today the detection limit for both methods is within the
range of several millimeters (Holzapfel et al., 2011; Canto et al.,
2012).
Since it is sometimes very difficult to differentiate between
the tumor and CP where CT and MRI remains equivocal, one
can use metabolic imaging. Positron emission tomography (PET)
is a non-invasive imaging technique that can assess functional
and metabolic activity of normal and diseased tissues. Depending
on the tracer used, it makes the evaluation of various cellular
functions possible, from glucose metabolism to synthetic capac-
ity of the cell to the resulting tissue hypoxia to cellular division
(Juweid and Cheson, 2006; Herrmann et al., 2012). In 1924, the
German biochemist Otto Warburg observed that, unlike normal
cells, which use oxidative phosphorylation for energy produc-
tion, cancer cells rely heavily on the less efficient glycolysis to
produce ATP.However, by favoring glycolysis over oxidative phos-
phorylation, malignant cells can spare their pyruvate to make
the carbon skeletons necessary for the new nucleic acid, and
membrane synthesis required for cellular growth (Kelloff et al.,
2005). Another advantage of glycolysis becomes obvious in the
oxygen-poor conditions that exist in several solid tumors, which
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FIGURE 6 | Schematic comparison of the therapeutic time window between pancreatic ductal adenocarcinoma and the intraductal papillary
mucinous neoplasia (Yamao et al., 2000; Salvia et al., 2004; Sohn et al., 2004; Yachida et al., 2010; Matthaei et al., 2011).
render oxidative phosphorylation less efficient (Jaeschke et al.,
2004). This metabolic dichotomy between the normal and cancer-
ous cells allows PET to differentiate between the two. Currently,
the most commonly used tracer is the glucose analog fluorine-
18 (18F) fluorodeoxyglucose (FDG) (Figure 7D). Despite a high
sensitivity, FDG has been reported to accumulate also in inflam-
matory lesions, thereby reducing the specificity of FDG-PET
(Buck et al., 2001). New, potentially more specific radiopharma-
ceuticals for clinical PET imaging have been introduced, such
as the thymidine analog 3′-deoxy-3′-[18F]fluorothymidine (FLT)
(Shields et al., 1998). In 41 patients undergoing pancreatic resec-
tion (33 malignant, 8 benign), Hermann et al. showed that, FDG
PET and FDG PET/CT showed a higher sensitivity but lower
specificity than FLT PET. Interestingly, visual analysis of FLT PET
led to two false-positive findings by misinterpreting physiolog-
ical bowel uptake as pathological FLT uptake in the pancreas
(Herrmann et al., 2012). Since PSC also divide in the activated
stroma, it is likely that the false-positive signal may partially
reflect the stromal proliferation (Erkan et al., 2012c).
MOLECULAR IMAGING IN PDAC TO DETECT EARLY
CARCINOGENESIS
Although the standard methods for diagnosing PDAC have
improved due to developments in hardware and software of
instruments, the detection limit of MRI, CT /PET-CT, and
endosonography is still far beyond the threshold which is needed
to detect precancerous lesions at an early stage (Holzapfel et al.,
2011; Canto et al., 2012; Herrmann et al., 2012). Recently Canto
et al. compared the accuracy of endoscopic ultrasonography,
MRI, and CT in detecting pancreatic anomalies in 225 high-
risk individuals for developing pancreatic cancer. Among the
methods analyzed, endosonography had the best accuracy (43%)
followed by MRI (33%) and CT (11%) (Canto et al., 2012). This
study also showed the superiority of all methods in detecting
cystic tumors compared to solid tumors. Since these results are
far from being ideal in detecting early cancer, several research
groups are focusing their resources into developing biomarkers
and radiological probes for the detection of early cancer using
molecular imaging. Since molecular imaging methods are only
as accurate as the biomarker used, the identification of a tumor
specific biomarker is the first limiting step in molecular imag-
ing. Ideally, the specific target should only be expressed by tumor
cells and not in the healthy tissue (or vice versa). After hav-
ing identified the molecular target, molecular probes have to be
developed which specifically bind to the target and amplify the
signal. Low toxicity and easy labeling are also important features.
Other limiting factors for the successful clinical application for
molecular imaging are the impaired tumor vasculature which
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FIGURE 7 | Cross sectional imaging of an uncinate process ductal
adenocarcinoma using tools of conventional radiology. (A) Computed
tomography using intravenous contrast enhancement (arterial phase) shows
the delayed contrast uptake of the fibrotic tumor (darker) compared to the
normal pancreas (lighter). (B)Data acquisition during the venous phase shows
an increase of contrast difference due to the reduced perfusion of the fibrotic
tumor compared to that of the normal pancreas. (C)Contrast enhanced imaging
using magnetic resonance imaging showing the tumor also darker than the
normal pancreas due to the delay in contrast uptake. (D) Positron emission
tomography using radiolabeled glucose (Fluorodeoxyglucose18 ) shows the
increased tracer uptake in the tumor compared to that of the normal pancreas.
IVC, Inferior vena cava; A, Aorta.
diminishes the delivery of the probe to the target and overcom-
ing of biological barriers such as the endothelium (Mahmood and
Weissleder, 2002). Among many others, cathepsin-based imaging
(Cruz-Monserrate et al., 2011; Eser et al., 2011), aptamers (Kim
et al., 2011; Lassalle et al., 2012), integrin receptor ligands
(Ahmed et al., 2002; Bandyopadhyay and Raghavan, 2009;
Kimura et al., 2012), high molecular weight probes such as
monoclonal antibodies or recombinant proteins coupled to mag-
netofluorescent nanoparticles (Zaman et al., 2011; Kelly et al.,
2008) have shown promising results in detecting premalig-
nant lesions and/or early stage cancer in experimental settings.
Imaging using targeted nanoparticles does not only image the
tumor, but also gives the possibility to deliver therapeutic agents.
This combined application is termed as “theranostics,” a port-
manteau of therapeutics and diagnostics (Picard and Bergeron,
2002).
STROMA-IMAGING
Since there is a strong stromal reaction around the precur-
sor lesions of PDAC, molecular imaging of the stromal activa-
tion might be a promising tool to identify precancerous lesions
at very early stages where those can be removed by surgi-
cal means. However, molecular imaging of stromal activation
is not very well studied so far with differentiating between
inflammatory and tumor-activated stroma being the biggest
obstacle (Figure 8). Dynamic contrast-enhanced MRI which is
used to detect morphologic characteristics of the tumor vascu-
lature is one method which helps to assess the stromal com-
partment. Farace et al. used for example small molecular and
albumin-binding contrast agents and demonstrated that the con-
trast distribution using dynamic contrast-enhanced MRI was
related to the stromal content of the tumor (Farace et al., 2011).
Recently Venkatasubramanian have summarized the data on
imaging of the ECM (Venkatasubramanian, 2012). The combined
use of multiphoton microscopy and second harmonic generation
imaging can detect differences in the collagen composition of the
ECM (Venkatasubramanian, 2012). In esophageal and breast can-
cer, it is shown that the stroma of the cancer is “different” than
the normal stroma in terms of reorganization of type I colla-
gen fibrils and fibers (Provenzano et al., 2006; Zhuo et al., 2009).
However these techniques have not been yet applied to pancreatic
cancer.
A promising stroma specific protein which can be used
to identify tumor-activated PSC is periostin. This ECM pro-
tein is exclusively produced by activated PSC in the pancreas
and shows a 42-fold higher expression in PDAC compared
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FIGURE 8 | Correlation of postoperative high resolution T2 weighted
magnetic resonance imaging with microscopic findings. (A) The resected
pancreatic head is cut open along the white double headed arrow. Red circle
marks the desmoplastic uncinate process tumor. (B) High resolution ex vivo
T2 weighted imaging of the resected specimen using magnetic resonance
imaging showing high fidelity of the macroscopic texture. However the
resolution is not enough to distinguish early lesions (i.e., PanIN III) with their
size of micro- to millimeter. (C) Uncinate process in close-up showing the
mixture of cancer and chronic pancreatitis-like changes within the stroma. (D)
Sampling of the tumor for histologic analysis (E) Hematoxylin + Eosin
staining of the sampled are shows the mixture of tumor and chronic
pancreatitis like changes within the tumor stroma.
to normal pancreas tissue (Erkan et al., 2007a). Furthermore,
periostin is a secretory protein that accumulates in the ECM
amplifying the amount of target to detect. In humans and in
GEMM, highest periostin expression is always found on the
activated front of the stroma; between normal pancreas and
the tumor. Precancerous lesions like PanIN and atypical flat
lesions are commonly found in this zone (Erkan et al., 2012b,c).
Therefore, using periostin as biomarker for detecting changes in
the stromal compartment has to be assessed in future imaging
approaches.
CONCLUSION
Our understanding of pancreatic cancer is shifting away from
a disease of malignant ductal cells-only, toward a complex sys-
tem where tumor evolution is a result of interaction of cancer
cells with their microenvironment. This change has led to inten-
sification of research focusing on the fibrotic stroma of PDAC.
Prior to the identification of PSC and their impact on pancre-
atic stroma, the presence or absence of pancreatic fibrosis has
influenced the decisions of surgeons intraoperatively over many
decades. A soft pancreas is a known risk factor for any operation
on the pancreas. Appreciation of this phenomenon was mostly a
result of trial and error without understanding the mechanisms
behind it. As of today, due to better cooperation of clinicians and
basic scientist interested in translational research, such clinical
problems are better analyzed and solved using tools of molecular
biology.
The two main obstacles in the effective treatment of PDAC
are late diagnosis and inherent therapy resistance of the tumor.
We now understand that both are influenced by the abundant
stroma seen in PDAC. The very poor and unchanged prognosis of
PDAC patients since years emphasizes the urgent need for early
detection methods (Schneider et al., 2005; Jemal et al., 2011). In
recent years molecular imaging emerged as a promising tool for
detecting precancerous lesions at a very early stage when surgical
intervention and chemotherapy is still a therapeutic option. Still,
there are some hurdles in the development of molecular imaging
methods such as the detection limits that are often too low
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(Holzapfel et al., 2011; Canto et al., 2012; Herrmann et al., 2012)
as well as the toxicity in humans since most of the methods have
only been tested in GEMM or xenograft models. Periostin might
be a suitable marker for imaging the stroma in PDAC. It is a
highly stroma specific protein and its expression precedes that of
alpha-smooth muscle actin expression by PSC in humans (Erkan
et al., 2007a, 2009).
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